CORE BIOGENSIS -Strasbourg, France-, provides next-generation recombinant proteins for cell manufacturing industries. Rooted by the principles of the bioeconomy, the company delivers its exclusive Ultra-Scalable Biomanufacturing as a Service (UBaaS) platform for the benefit of business leaders, scientists, and ultimately patients in the field of advanced therapies. By employing proprietary genetic engineering, plant biology, protein expression and purification technologies, the company offers high quality products, which improve the standards of bioactivity and purity for cell culture, while being produced at the scale and costs needed for cellular therapies. Their portfolio counts with a wide list of growth factors, cytokines, and cell culture supplements for pluripotent, mesenchymal, and immune cells. More importantly, their supply solutions enable for stock security and long-term use batch reservation, thanks to the natural preservation of the proteins in the bioproduction platform.
Core Biogenesis is dedicated to improving our present and future lives by re-connecting scientific advancements to natural resources, and ensuring scalability, sustainability and worldwide accessibility for the medicines that define the future of health. Established from scientific rigor and entrepreneurial vision, our fast-growing team is fostered by diversity and inclusion in science, business, and technology, and we are fully devoted to help those making the world a better place through the discovery of novel treatments for life devastating diseases.
VISIT WEBSITE